Airway mucosal host defense is key to genomic regulation of cystic fibrosis lung disease severity

American Journal of Respiratory and Critical Care Medicine

Volumn 197, Issue 1, 2018, Pages 79-93

  Polineni, Deepika ^a,b   Dang, Hong ^b   Gallins, Paul J ^d   Jones, Lisa C ^b   Pace, Rhonda G ^b   Stonebraker, Jaclyn R ^b   Commander, Leah A ^b   Krenicky, Jeanne E ^g   Zhou, Yi Hui ^d   Corvol, Harriet ^h,i   Cutting, Garry R ^e,j   Drumm, Mitchell L ^g   Strug, Lisa J ^l,o   Boyle, Michael P ^k   Durie, Peter R ^m,n,o   Chmiel, James F ^g   Zou, Fei ^c   Wright, Fred A ^e,f   O’Neal, Wanda K ^b   Knowles, Michael R ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b School of Medicine   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d Bioinformatics Research Center   (United States)

^e Department of Statistics ^*  (United States)

^f NORTH CAROLINA STATE UNIVERSITY   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h ARMAND TROUSSEAU HOSPITAL   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Program in Genetics and Genome Biology   (United States)

^m Physiology and Experimental Medicine Research Program   (United States)

ⁿ HOSPITAL FOR SICK CHILDREN   (Canada)

^o UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Cystic fibrosis; Epithelia; Genome; Genome wide association study; Transcriptome

Indexed keywords

ADOLESCENT; ADULT; ALLELE; APOPTOSIS; ARTICLE; CHILD; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENETIC RISK; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HLA SYSTEM; HOST RESISTANCE; HUMAN; IN VIVO STUDY; INNATE IMMUNITY; ION TRANSPORT; LIPID METABOLISM; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; RESPIRATORY MUCOSA; RNA SEQUENCE; TRANSCRIPTOMICS; VIRUS INFECTION; COHORT ANALYSIS; COMPLICATION; DISEASE EXACERBATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC VARIATION; GENETICS; NOSE MUCOSA; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; RNA;

ADOLESCENT; ADULT; COHORT STUDIES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; LUNG DISEASES; MALE; NASAL MUCOSA; PROGNOSIS; RISK ASSESSMENT; RNA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85039872867     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201701-0134OC     Document Type: Article

References (46)

1. Mekus F, Ballmann M, Bronsveld I, Bijman J, Veeze H, Tümmler B. Categories of DF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin Res 2000;3: 277–293.
2. Cystic Fibrosis Foundation Patient Registry. 2015 Annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2016 [accessed 2016 Dec 5]. Available from: https://www.cff.org/Our-Research/CF-PatientRegistry/2015-Patient-Registry-Annual-Data-Report.pdf.
3. Vanscoy LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 2007;175:1036–1043.
4. Collaco JM, Blackman SM, McGready J, Naughton KM, Cutting GR. Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. J Pediatr 2010;157: 802–807.e3.
5. Corvol H, Blackman SM, Boëlle PY, Gallins PJ, Pace RG, Stonebraker JR, et al. Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nat Commun 2015;6: 8382.
6. O’Neal WK, Gallins P, Pace RG, Dang H, Wolf WE, Jones LC, et al. Gene expression in transformed lymphocytes reveals variation in endomembrane and HLA pathways modifying cystic fibrosis pulmonary phenotypes. Am J Hum Genet 2015;96:318–328.
7. Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 2011;43:539–546.
8. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, et al. Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2005;172: 885–891.
9. Taylor C, Commander CW, Collaco JM, Strug LJ, Li W, Wright FA, et al. A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis genetic modifier studies. Pediatr Pulmonol 2011;46: 857–869.
10. Rowe SM, Liu B, Hill A, Hathorne H, Cohen M, Beamer JR, et al. VX06-770-101 Study Group. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PLoS One 2013;8: e66955.
11. McDougall CM, Blaylock MG, Douglas JG, Brooker RJ, Helms PJ, Walsh GM. Nasal epithelial cells as surrogates for bronchial epithelial cells in airway inflammation studies. Am J Respir Cell Mol Biol 2008; 39:560–568.
12. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991;325:533–538.
13. Polineni D, Dang H, Pace RG, Stonebraker JR, Guo XL, Jones LC, et al. Correlation of inflammatory markers in human nasal epithelia in vivo informs transcriptomic studies in cystic fibrosis (CF) complementary to genomic variation studies. Am J Respir Crit Care Med 2014;189: A5519. (abstract).
14. Polineni D, Dang H, Gallins PJ, Pace R, Stonebraker JR, Jones LC, et al. In vivo human nasal epithelia inform transcriptomic studies in cystic fibrosis (CF) complementary to genomic variation studies. Pediatr Pulmonol 2014;49:272. (abstract).
15. Polineni D, Dang H, Pace RG, Stonebraker JR, Guo XG, Jones LC, et al. In vivo cystic fibrosis (CF) nasal epithelial transcriptomic studies reveal non-CFTR differential gene expression associated with CF lung disease severity. Am J Respir Crit Care Med 2016;193:A6458. (abstract).
16. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 2012;28:882–883.
17. Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics 2012;28:1353–1358.
18. Barry WT, Nobel AB, Wright FA. Significance analysis of functional categories in gene expression studies: a structured permutation approach. Bioinformatics 2005;21:1943–1949.
19. Wright FA, Sullivan PF, Brooks AI, Zou F, Sun W, Xia K, et al. Heritability and genomics of gene expression in peripheral blood. Nat Genet 2014;46:430–437.
20. Gene Set Enrichment Analysis (GSEA)/Broad Institute. GSEA user guide, version 5.1 [accessed 2016 Apr 4]. Available from: http://software.broadinstitute.org/gsea/doc/GSEAUserGuideFrame.html.
21. Schaid DJ, Sinnwell JP, Jenkins GD, McDonnell SK, Ingle JN, Kubo M, et al. Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies. Genet Epidemiol 2012;36:3–16.
22. Pankow S, Bamberger C, Calzolari D, Martínez-Bartolomé S, Lavallée-Adam M, Balch WE, et al. ΔF508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature 2015;528:510–516.
23. Bruscia EM, Bonfield TL. Innate and adaptive immunity in cystic fibrosis. Clin Chest Med 2016;37:17–29.
24. Adam D, Roux-Delrieu J, Luczka E, Bonnomet A, Lesage J, Mérol JC, et al. Cystic fibrosis airway epithelium remodelling: involvement of inflammation. J Pathol 2015;235:408–419.
25. Flight WG, Bright-Thomas RJ, Tilston P, Mutton KJ, Guiver M, Morris J, et al. Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis. Thorax 2014;69:247–253.
26. Hendricks MR, Bomberger JM. Digging through the obstruction: insight into the epithelial cell response to respiratory virus infection in patients with cystic fibrosis. J Virol 2016;90:4258–4261.
27. Wright JM, Merlo CA, Reynolds JB, Zeitlin PL, Garcia JG, Guggino WB, et al. Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease. Am J Respir Cell Mol Biol 2006; 35:327–336.
28. Hillian AD, Londono D, Dunn JM, Goddard KAB, Pace RG, Knowles MR, et al. CF Gene Modifier Study Group. Modulation of cystic fibrosis lung disease by variants in interleukin-8. Genes Immun 2008;9:501–508.
29. Dang H, Gallins PJ, Pace RG, Guo XL, Stonebraker JR, Corvol H, et al. Novel variation at chr11p13 associated with cystic fibrosis lung disease severity. Hum Genome Var 2016;3:16020. [Published erratum appears in Hum Genome Var 2017;4:17016.]
30. Stolzenburg LR, Yang R, Kerschner JL, Fossum S, Xu M, Hoffmann A, et al. Regulatory dynamics of 11p13 suggest a role for EHF in modifying CF lung disease severity. Nucleic Acids Res 2017;45: 8773–8784.
31. Fossum SL, Mutolo MJ, Tugores A, Ghosh S, Randell SH, Jones LC, et al. Ets homologous factor (EHF) has critical roles in epithelial dysfunction in airway disease. J Biol Chem 2017;292: 10938–10949.
32. Wang L, Ko ER, Gilchrist JJ, Pittman KJ, Rautanen A, Pirinen M, et al.; Wellcome Trust Case Control Consortium 2; Kenyan Bacteraemia Study Group. Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis. Sci Adv 2017;3:e1602096.
33. Ko DC, Gamazon ER, Shukla KP, Pfuetzner RA, Whittington D, Holden TD, et al. Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. Proc Natl Acad Sci USA 2012;109:E2343–E2352.
34. Kontakioti E, Domvri K, Papakosta D, Daniilidis M. HLA and asthma phenotypes/endotypes: a review. Hum Immunol 2014;75: 930–939.
35. Lasky-Su J, Himes BE, Raby BA, Klanderman BJ, Sylvia JS, Lange C, et al.; SHARP investigators. HLA-DQ strikes again: genome-wide association study further confirms HLA-DQ in the diagnosis of asthma among adults. Clin Exp Allergy 2012;42:1724–1733.
36. Quinn RA, Whiteson K, Lim YW, Zhao J, Conrad D. LiPuma JJ, Rohwer F, Widder S. Ecological networking of cystic fibrosis lung infections. NPJ Biofilms Microbiomes 2016;2:4.
37. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al.; TRAFFIC Study Group. TRANSPORT Study Group. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015;373:220–231.
38. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365: 1663–1672.
39. Torphy TJ, Allen J, Cantin AM, Konstan MW, Accurso FJ, Joseloff E, et al.; Antiinflammatory Therapy Working Group. Considerations for the conduct of clinical trials with antiinflammatory agents in cystic fibrosis: a Cystic Fibrosis Foundation Workshop report. Ann Am Thorac Soc 2015;12:1398–1406.
40. Nichols DP, Chmiel JF. Inflammation and its genesis in cystic fibrosis. Pediatr Pulmonol 2015;50:S39–S56.
41. Mary C, Duek P, Salleron L, Tienz P, Bumann D, Bairoch A, et al. Functional identification of APIP as human mtnB, a key enzyme in the methionine salvage pathway. PLoS One 2012;7:e52877.
42. Kang W, Hong SH, Lee HM, Kim NY, Lim YC, Le TM, et al. Structural and biochemical basis for the inhibition of cell death by APIP, a methionine salvage enzyme. Proc Natl Acad Sci USA 2014;111: E54–E61.
43. Esther CR Jr, Coakley RD, Henderson AG, Zhou YH, Wright FA, Boucher RC. Metabolomic evaluation of neutrophilic airway inflammation in cystic fibrosis. Chest 2015;148:507–515.
44. Basu I, Locker J, Cassera MB, Belbin TJ, Merino EF, Dong X, et al. Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 59-methylthioadenosine phosphorylase. J Biol Chem 2011;286:4902–4911.
45. Esther CR, O’Neal W, Polineni D, Mahon A, Isaacman S, Knowles M. A combined’omics strategy identifies the methionine salvage pathway as a novel therapeutic target for cystic fibrosis airways disease. Am J Respir Crit Care Med 2017;195:A4852. (abstract).
46. Saini Y, Dang H, Livraghi-Butrico A, Kelly EJ, Jones LC, O’Neal WK, et al. Gene expression in whole lung and pulmonary macrophages reflects the dynamic pathology associated with airway surface dehydration. BMC Genomics 2014;15:726.